Print Page   |   Contact Us   |   Sign In   |   Join
Business Wire Life Sciences News (US)
Share |

AXIS,, and Uptake to Keynote Domino Data Lab’s 2nd Annual Data Science Pop-Up in ChicagoOpen in a New Window

CHICAGO--(BUSINESS WIRE)--Domino Data Lab, a leading platform for data science acceleration, has announced the keynote speakers for its 2nd Annual Data Science Pop-Up event in Chicago. Meghan Anzelc, vice president of data and analytics, AXIS; Adam Mcelhinney, vice president of data science, Uptake; and, Addhyan Pandey, principal data scientist,, will present the current and future trends in data science. The event will be held Tuesday, November 14th at 1871, Chicago’s Center for Techn


Adobe Sign Certified Compliant with SAFE-BioPharma StandardOpen in a New Window

TENAFLY, N.J.--(BUSINESS WIRE)--#CyberSecurity--Adobe Sign e-signature solution certified compliant with global SAFE-BioPharma standard


Reemo Health Expands Executive Leadership Team with Former Teradata VPsOpen in a New Window

MINNEAPOLIS--(BUSINESS WIRE)--Reemo Health is pleased to announce the addition of Jose Basa and Peter Obringer to its executive leadership team.


Dune Medical Expands Leadership Team in Atlanta, Naming Skip Ashmore as CCO and Susan Turner as VP Healthcare Economics & ReimbursementOpen in a New Window

ATLANTA--(BUSINESS WIRE)--Dune Medical Devices has appointed Skip Ashmore as Chief Commercial Officer. Ashmore joins Dune with 25 years of experience in the medical device industry including engagements with Covidien, CryoLife, Baxter Healthcare and Motus GI. “Having worked with Skip at Covidien, I have seen first-hand his ability to integrate his background in the sciences with a market driven, customer focus to the business,” says Lori Chmura, Dune Medical CEO. “His expertise enhances our tea


Rite Aid’s Medicare Advisor Tool Returns to Help Medicare Beneficiaries Select Prescription Drug Coverage for 2018Open in a New Window

CAMP HILL, Pa.--(BUSINESS WIRE)--As the annual Medicare Part D enrollment period gets underway, from now through Dec. 7, 2017, Rite Aid pharmacies nationwide are providing senior customers with free resources to help select the right prescription drug plan (PDP) or update their existing coverage for 2018. Patients and caregivers can use Rite Aid's dedicated Medicare Advisor comparison tool available at and in all Rite Aid pharmacies, to request the three lowest-c


Napo Pharmaceuticals Endorses Prevention Access Campaign’s U=U Consensus Statement for People Living With HIV/AIDS (PLWHA)Open in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals endorses Prevention Access Campaign’s U=U Consensus Statement for people living with HIV/AIDS.


Prometric and Board of Pharmacy Specialities® Begin PartnershipOpen in a New Window

BALTIMORE--(BUSINESS WIRE)--Prometric, a trusted provider of market-leading test development and delivery solutions, was selected by the Board of Pharmacy Specialties® (BPS), to provide best-in-class test delivery services for its board certification examinations to more than 7,500 candidates annually. Established in 1976, the mission of the BPS is to improve patient care by promoting the recognition and value of specialized training, knowledge, and skills in pharmacy and specialty board certif


Altasciences Conducts Alcohol Drug-Drug Interaction Study for Amygdala Neurosciences Inc.Open in a New Window

OVERLAND PARK, Kansas--(BUSINESS WIRE)--#POC--Vince & Associates Clinical Research, an Altasciences company, announced today that they are working with Amygdala Neurosciences Inc. to conduct a Phase 1b, proof-of-concept, dose-ranging study to evaluate the safety of the co-administration of ascending doses of ANS-6637 and ethanol in healthy male alcohol drinkers. The potential clinical indication for ANS-6637 is the treatment of substance abuse, including alcohol and cocaine dependence. Therefore,


FluGen Awarded $14.4 million by the Department of Defense to Test Universal Flu Vaccine Against Mismatched StrainsOpen in a New Window

MADISON, Wis.--(BUSINESS WIRE)--#DOD--FluGen Inc., announced today that it has been awarded a grant of $14.4 million through the DOD’s Congressionally Directed Medical Research Programs Peer Reviewed Medical Research Program’s (PRMRP) mechanism to conduct clinical challenge-studies against mismatched influenza strains with its lead universal flu vaccine, RedeeFlu™. Under the three-year award, FluGen will conduct two challenge-studies with RedeeFlu™. In these studies, half of the participants will be


Esri Founder and President Jack Dangermond to Discuss Earth Observations in the Commercial Sector at GEO WeekOpen in a New Window

REDLANDS, Calif.--(BUSINESS WIRE)--#Esri--Esri founder and president Jack Dangermond to discuss earth observations in the commercial sector at GEO Week.


Quad Technologies Patents Novel T-Cell Activation Reagent for Car-T Cell ManufacturingOpen in a New Window

WOBURN, Mass.--(BUSINESS WIRE)--Quad Technologies patents novel T-cell activation reagent for CAR-T cell manufacturing


Nation's Leading Fertility Therapy Company Appoints Life Sciences Veteran to Board of DirectorsOpen in a New Window

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--#Conceivex--Leading fertility therapy company adds veteran life sciences industry executive to its Board of Directors.


PPD Hero Leads Team Supporting Multiple Sclerosis ResearchOpen in a New Window

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Hero Leads Team Supporting Multiple Sclerosis Research; Company’s Texas employees join Walk MS: Austin to spotlight life-changing clinical trials


Synspira Announces First Patient Dosed in Phase 1a Study of SNSP113 in Cystic FibrosisOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synspira announced initiation of a Phase 1a first-in-human study of SNSP113, in development for use in pulmonary complications of cystic fibrosis.


Freenome Announces Formation of Scientific Advisory BoardOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#AI--Inaugural Members Include Leading Experts in Genomics and Machine Learning


SCORR Marketing and Applied Clinical Trials Release Report on Collaborative R&D in the Drug Development IndustryOpen in a New Window

KEARNEY, Neb.--(BUSINESS WIRE)--#healthscienceexperts--SCORR Marketing and Applied Clinical Trials have released a new study on collaboration in the life sciences industry.


Blade Therapeutics Announces Selection of a Clinical Development Candidate and Funding of the Second Tranche for its Series B FinancingOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs, today announced that it has nominated a clinical development candidate for its lead program focused on small molecule inhibitors that selectively target certain intracellular cysteine proteases. Selection of the clinical development candidate triggered funding of the remaining tranche for the $45 million U.S. Series B fina


Phytecs Expands Scientific Advisory Board with Leading Experts in Mental Health, Inflammation, Metabolism and the Endocannabinoid SystemOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--Phytecs, Inc., a biotechnology company exploring potential therapies that target the body’s endocannabinoid system (ECS) to treat disease, today announced the addition of new members to the company’s Scientific Advisory Board: Pal Pacher, M.D., Ph.D., is head of the Laboratory of Cardiovascular Physiology and Tissue Injury at the National Institute on Alcohol Abuse and Alcoholism and an adjunct professor in the Department of Anesthesiology at the University of Texa


10x Genomics Enables High-Volume Studies by Providing More Affordable Solutions for Whole Genome and Exome AnalysisOpen in a New Window

PLEASANTON, Calif.--(BUSINESS WIRE)--#ASHG17--10x Genomics Enables High-Volume Studies by Providing More Affordable Solutions for Whole Genome and Exome Analysis.


10x Genomics Announces the Addition of Unbiased Gene Expression and B-cell Repertoire to the Chromium Single Cell V(D)J SolutionOpen in a New Window

PLEASANTON, Calif.--(BUSINESS WIRE)--#ASHG17--10x Genomics announces the addition of unbiased gene expression and B-cell repertoire to the Chromium Single Cell V(D)J Solution.


RxAdvance Honored by Goldman Sachs for EntrepreneurshipOpen in a New Window

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--#DavidSolomon--Goldman Sachs (NYSE:GS) is recognizing RxAdvance President and CEO Ravi Ika as one of the 100 Most Intriguing Entrepreneurs of 2017 at its Builders + Innovators Summit in Santa Barbara, California. Goldman Sachs selected Ravi as one of 100 entrepreneurs from multiple industries to be honored at the two-day event. A noted entrepreneur and an innovator of disruptive business solutions, Ravi Ika founded RxAdvance in 2013 and serves as President and Chief Execu


Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar FasciitisOpen in a New Window

NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced it has completed enrollment of patients in the Company’s Phase 2 program investigating the use of DaxibotulinumtoxinA for Injection (RT002) for the management of plantar fasciitis. The study enrolled 59 subjects across five centers in the United States (US). The Company remains on track to


Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive ApproachOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) confirms its comprehensive approach to tackle MS at the seventh joint meeting of ECTRIMS/ACTRIMS.


Alnylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious DiseasesOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an exclusive licensing agreement with Vir Biotechnology, a company dedicated to transforming the care of people with serious infectious diseases, for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus (HBV) infection. As part of this agreement, the companies will advance Alnylam’s HBV program


Vir Biotechnology Builds Pipeline, Capabilities, and Lays Out Strategy to Address Serious Infectious DiseasesOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. today announced agreements with Humabs BioMed SA, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALYN), and Visterra, Inc., as well as four leading academic research institutions. Together with the company’s internal research and development capabilities, these achievements provide the foundation on which Vir will pursue its mission of transforming the care of people with serious infectious diseases. To support these efforts, Vir has secured financ Collaborates With UKCRC Tissue Directory and Coordination Centre to Ensure Quality of Human Biosample Acquisition GloballyOpen in a New Window

LONDON--(BUSINESS WIRE), the world’s leading marketplace for outsourced scientific services, today announced that it is entering into a collaboration with the UKCRC Tissue Directory and Coordination Centre (UKCRC TDCC) to support the work of biobanks throughout the United Kingdom. The partnership will enable drug R&D to move forward more quickly by making large collections of prescreened human biological samples available for scientific research. Through the new COMPLI™ featu


Visterra Announces Research Collaboration, Exclusive License, and Option Agreement for Infectious Diseases with Vir BiotechnologyOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra entered into a research collaboration/exclusive license/option agreement with Vir Biotechnology for up to 5 infectious disease programs.


Successful Treatment of Canine Brain Tumor Offers Hope to HumansOpen in a New Window

ROCKVILLE, Md.--(BUSINESS WIRE)--Successful Treatment of Canine Brain Tumor Offers Hope to Humans


New Program Aims to Accelerate Alignment Efforts in Identity and Access Management for Research and Education CommunityOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--#TechEX17--Internet2 announced today ten universities selected to participate in the year-long Trust and Identity in Education and Research (TIER) Campus Success Program that will provide guidance for institutions across the U.S. looking to implement identity and access management (IAM) solutions for their campuses. Modeled after two previous successful middleware adoption programs that Internet2 organized under National Science Foundation grants, the new program will focus ad


US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority ReviewOpen in a New Window

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental New Drug Application (sNDA) for the use of LYNPARZA® (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic


U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority ReviewOpen in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review


Merck’s KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with High Levels of PD-L1Open in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck’s KEYTRUDA More Than Doubled Median Overall Survival Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic NSCLC


Innovus Pharma Receives Approval from Health Canada for Vesele as a Natural Health ProductOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has received approval from Health Canada to market its best-selling, clinically proven Vesele® product as a Natural Health Product (“NHP”)


Anthem Launches IngenioRx, New Pharmacy Benefits ManagerOpen in a New Window

INDIANAPOLIS--(BUSINESS WIRE)--Anthem, Inc. (NYSE: ANTM), one of the nation’s largest health benefits companies, announced today it is establishing a new pharmacy benefits manager to be named IngenioRx. IngenioRx will begin offering a full suite of PBM solutions starting in 2020, which coincides with the conclusion of the company’s current PBM contract. “As a company, we continuously seek bold, innovative solutions that achieve consumer access to high quality, affordable healthcare,” said Josep


Dassault Systèmes’ Living Heart Project Reaches Next Milestones in Mission to Improve Patient CareOpen in a New Window

HOLLYWOOD, Fla.--(BUSINESS WIRE)--Dassault Systèmes (Paris:DSY) (Euronext Paris: #13065, DSY.PA) today outlined, at the 3DEXPERIENCE Forum North America, multiple milestones in its Living Heart Project aimed to drive the creation and use of simulated 3D personalized hearts in the treatment, diagnosis and prevention of heart diseases. As the scientific and medical community seeks faster and more targeted ways to improve patient care, the Living Heart Project is extending its reach through new pa


Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung CancerOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced updated results from its clinical trials, including the STARTRK-2 trial, of entrectinib - an investigational, CNS-active, potent, and selective tyrosine kinase inhibitor being developed for tumors that harbor NTRK fusions or ROS1 fusions. In this interim analysis, entrectinib demonstrated a 78% confirmed ORR (by Investigator; 95% CI: 60.0, 90.7) and a 69% c


Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in JapanOpen in a New Window

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer


Intermountain Healthcare Announces Precision Health Research Endeavors with 10x GenomicsOpen in a New Window

PLEASANTON, Calif. & ST. GEORGE, Utah--(BUSINESS WIRE)--#ASHG17--Intermountain Healthcare Announces Precision Health Research Endeavors with 10x Genomics


RenovaCare, Inc. Closes Registered Direct Offering and Concurrent Private PlacementOpen in a New Window

NEW YORK & PITTSBURGH & BERLIN--(BUSINESS WIRE)--RenovaCare, Inc., (OTCQB:RCAR), developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately 915,000 shares of common stock in a registered direct offering and common stock purchase warrants in a concurrent private placement. The offerings are


‘Keeping the Promise—AHF 30 Years’Open in a New Window

LOS ANGELES--(BUSINESS WIRE)--‘Keeping the Promise—AHF 30 Years’ - Documentary film screening & reception Thurs., Oct. 19 at Hollywood’s historic Arclight Cinerama Dome Theater


AgModels, Cornell Cooperative Extension and The New York City Watershed Agricultural Program Team Up to Help Dairy Farms and the EnvironmentOpen in a New Window

SYRACUSE, N.Y.--(BUSINESS WIRE)--AgModels, Cornell Coop. Extension and NYC Watershed Program make Precision Feed Management Tool Available Online to Help Dairy Farms & Water Quality


Most Energy Efficient Performance in Ultra-Low Temperature Technology on Exhibit at I2SL, BostonOpen in a New Window

WOOD DALE, Ill.--(BUSINESS WIRE)--#I2SL--ENERGY STAR® Certified, 25.7 cu.ft. -86°C freezer on display at I2SL, Boston, illustrates most energy efficient ULT freezer technology.


IntriCon to Announce 2017 Third-Quarter Results on Monday, November 6Open in a New Window

ARDEN HILLS, Minn.--(BUSINESS WIRE)--IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of body-worn devices, today announced that it will release its 2017 third-quarter results on Monday, November 6, 2017, at market close. Following the release, the company will hold an investment community conference call on the same day, beginning at 4:00 p.m. CT. Mark Gorder, president and chief executive officer, and Scott Longval, chief financial officer, will review t


BioTime, Inc. Announces Closing of Public Offering and Underwriters’ Full Exercise of Over-Allotment OptionOpen in a New Window

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced public offering of 9,615,385 shares of common stock, including 1,442,308 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The offering price to the public was $2.60 p


Bovie Medical Corporation to Release Third Quarter 2017 Financial Results on November 2, 2017Open in a New Window

CLEARWATER, Fla.--(BUSINESS WIRE)--Bovie Medical (NYSE American: BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the third quarter of 2017 will be released after the market closes on Thursday, November 2. Management will host a conference call at 4:30 p.m. Eastern Time on November 2 to discuss the results of the quarter and host a question and answer session. To listen to the call by phone,


As Patent Expires, AHF Calls on Gilead for 90% Price Reduction on Tenofovir-based Drugs, Including TruvadaOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--As Patent Expires, AHF Calls on Gilead for 90% Price Reduction on Tenofovir-based Drugs, Including Truvada


Exomedicine Institute Appoints Pam Platt as Chief StorytellerOpen in a New Window

LEXINGTON, Ky.--(BUSINESS WIRE)--Veteran journalist Pam Platt joins Exomedicine Institute as Chief Storyteller to share stories emerging from new field of medical research in space.


Walgreens to Establish New Technology Center of Excellence in the Sullivan CenterOpen in a New Window

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens today announced with Chicago Mayor Rahm Emanuel that it will bring approximately 300 technology positions to its current downtown Chicago office in the Sullivan Center to establish a new technology center of excellence. Through a combination of new hires and relocations from its Deerfield, Ill., support office, Walgreens will double its number of employees working at the Sullivan Center, located at 36 S. Wabash Ave. Walgreens is currently building out


Trends Spotlight: Three Areas of Focus to Reduce CLABSIsOpen in a New Window

NORTHFIELD, Ill.--(BUSINESS WIRE)--CEO of the Association for Vascular Access (AVA) discusses trends the organization recognizes will help reduce readmissions.


DebMed Offers Guidance for Improving Hand Hygiene Compliance in Healthcare Facilities in Recognition of International Infection Prevention Week, Oct. 15-21Open in a New Window

CHARLOTTE, N.C.--(BUSINESS WIRE)--In honor of International Infection Prevention Week, DebMed is offering tips to improve hand hygiene compliance within healthcare facilities.


Derek Griffith Named Executive Vice President of Store OperationsOpen in a New Window

CAMP HILL, Pa.--(BUSINESS WIRE)--Rite Aid Corporation (NYSE: RAD) today announced that Derek Griffith, Rite Aid’s current senior vice president of operations in the Northeast and Midwest, has been named executive vice president of store operations. In this position, Griffith will be responsible for all aspects of the company’s chainwide store operations. He will report to Bryan Everett, chief operating officer of Rite Aid stores. “Derek is a seasoned retail operator with demonstrated expertise


Dr. David Walt of Wyss Institute to Speak at Powering Precision Health 2017Open in a New Window

BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--#PPH--Powering Precision Health 2017, the nation’s first precision health summit, announces Dr. David Walt will speak at the summit on October 24th.


Battelle, Rare Earth Salts Team on Department of Energy ProjectOpen in a New Window

COLUMBUS, Ohio & BEATRICE, Neb.--(BUSINESS WIRE)--Battelle is teaming with Rare Earth Salts (RES) on a potentially groundbreaking project for the United States Department of Energy’s National Energy Technology Laboratory. The project, Recovery of High Purity Rare Earth Elements (REEs) from Coal Ash via a Novel Separations Process, will produce valuable Rare Earth Oxides from coal fly ash, converting them to the high purities necessary for a saleable product. The two organizations will advance t


AskBio and Columbus Venture Partners Launch Gene Therapy Company ViralgenOpen in a New Window

CHAPEL HILL, N.C.--(BUSINESS WIRE)--AskBio Pharmaceuticals and Columbus Venture Partners Launch Gene Therapy Company Viralgen


McKesson Partners with Lyft to Support California Wildfire VictimsOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--To help support the transportation needs of individuals and families affected by the wildfire in the Northern California area, McKesson has partnered with Lyft to provide complimentary rides to local hospitals or treatment centers. Today’s partnership follows on McKesson’s donation of $100,000 to the American Red Cross in support of wildfire relief efforts. “Because of the North Bay fires, even getting to treatment centers remains a challenge for many patients. T


Median Technologies to Attend The Liver Meeting® of The American Association for the Study of Liver Diseases to Be Held October 20-24, 2017 in Washington, DC, USAOpen in a New Window

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT), the Imaging Phenomics Company®, announced today that it will participate in The Liver Meeting®, the annual meeting of the Association for the Study of Liver Diseases (AASLD) October 20-24 at the Walter E. Washington Convention Center, Washington DC, USA. The industry exhibition will be opened from Oct 21st to Oct. 23rd. The company’s scientific and business team will demonstrate Median’s imaging pheno


Mauna Kea Technologies Appoints Olivier Regnard as Deputy CEO And Chief Financial OfficerOpen in a New Window

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the appointment of Olivier Regnard to the position of Deputy Chief Executive Officer and Chief Financial Officer, effective immediately. Mr. Regnard brings nearly 20 years of finance, accounting and operational experience to the Company and already has familiarity with Mauna Kea Technologies, hav


Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis BOpen in a New Window

STRASBOURG, France--(BUSINESS WIRE)--#HBV--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, will be presenting a poster on TG1050 first promising clinical results at the American Association for the Study of Liver Diseases (AASLD) Meeting 2017, in Washington, DC, October 20-24. TG1050 is a therapeutic vaccine, that is currently being evaluated in an international first-in-man Phase 1/1b trial in patients with chroni


The Allen Institute of Artificial Intelligence (AI2) Adds Over 30 Million Biomedical Papers to Semantic Scholar to Help the Medical Community Fight Information Overload and Save LivesOpen in a New Window

SEATTLE--(BUSINESS WIRE)--The Allen Institute for Artificial Intelligence (AI2) today announced its AI-based academic search engine, Semantic Scholar, has made significant progress with the addition of tens-of-millions of biomedical papers. Semantic Scholar enables deep information extraction and entity linking to create a scientific knowledge graph out of the insights buried in millions of documents. Semantic Scholar now covers neuroscience, computer science and biomedical papers and is tracki


Powering Precision Health 2017 Announces World-Renowned Keynote LineupOpen in a New Window

BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--#CTE--Powering Precision Health 2017, the nation’s first precision health summit, today announced its lineup of world-renowned featured keynoters.


SwRI Expands Automotive Research Footprint with Laboratory in Ann ArborOpen in a New Window

SAN ANTONIO--(BUSINESS WIRE)--Test cells improve support for Detroit-area clients


Cleveland Clinic Joins PierianDx’s Customer Network to Accelerate Precision MedicineOpen in a New Window

ST. LOUIS--(BUSINESS WIRE)--Cleveland Clinic chooses PierianDx platform to accelerate precision medicine.


BioFlorida, Inc. | 6742 Forest Hill Blvd., Suite 256 | West Palm Beach, FL 33413
(P) 561-653-3839
Membership Management Software Powered by YourMembership  ::  Legal